Dynavax at William Blair Conference: Strategic Growth Insights

Dynavax Technologies (DVAX) presented at the William Blair Growth Stock Conference, with CEO Ryan Spencer highlighting the company's focus on expanding HEPLISAV B's market share to over 60% of the U.S. hepatitis B vaccine market, potentially valued at $900 million by 2030. Dynavax maintains a strong financial position with over $660 million in cash and reiterated its 2025 revenue guidance for HEPLISAV B at $305 million to $325 million, expecting to reach the upper end of the range, while also advancing its vaccine pipeline, including shingles and plague programs. The company has nearly completed a $200 million share buyback program, reflecting its capital allocation strategy.

Analysis

Dynavax Technologies Corporation (DVAX) presented a compelling growth narrative at the William Blair Growth Stock Conference, centered on its HEPLISAV B adult hepatitis B vaccine and the strategic leveraging of its CpG 1018 adjuvant technology. The company reiterated its 2025 HEPLISAV B revenue guidance of $305 million to $325 million, noting trends towards the upper end, and aims to capture over 60% of a U.S. market projected to exceed $900 million by 2030. This ambition is supported by HEPLISAV B's current strong market penetration, exceeding 58% in retail settings and 50% in prioritized clinics, and its competitive advantage of a two-dose regimen over one month compared to the competitor's three doses over six months. Dynavax maintains a robust financial position with over $660 million in cash as of Q1 2025 and projects adjusted EBITDA to surpass $75 million for the year. This financial health fuels a balanced capital allocation strategy that includes advancing its clinical pipeline—notably a shingles vaccine program with Phase 1/2 data expected in Q3 2025, a DoD-funded plague vaccine entering Phase 2 in H2 2025, and earlier-stage programs for pandemic influenza and Lyme disease—as well as returning capital to shareholders, evidenced by a nearly completed $200 million share buyback program. The company's strategy also includes seeking late-stage vaccine acquisitions to further utilize its commercial infrastructure.

Key Decisions for Investors

• Investors should closely monitor HEPLISAV B's revenue performance against its $305-$325 million guidance for 2025 and its progress towards achieving over 60% share in the expanding U.S. hepatitis B vaccine market, which is projected to reach $900 million by 2030.
• The upcoming Q3 2025 topline data from the Phase 1/2 shingles vaccine trial is a key near-term catalyst; positive results demonstrating improved tolerability compared to existing treatments could significantly enhance the asset's value and Dynavax's growth prospects.
• Consider Dynavax's disciplined capital allocation, including the impact of the $200 million share repurchase program (85% complete) and the potential for value-accretive late-stage asset acquisitions, leveraging its strong cash position of over $660 million.
• Evaluate the progress of Dynavax's pipeline beyond shingles, particularly the DoD-funded plague vaccine program entering Phase 2 and early developments in pandemic influenza and Lyme disease, as these represent long-term growth opportunities driven by the CpG 1018 adjuvant technology.